All articles tagged with #saxenda
The FDA approved Teva Pharmaceutical's generic version of Saxenda, a weight-loss drug by Novo Nordisk, marking the first generic GLP-1 product for weight loss, potentially offering a lower-cost alternative and impacting Novo Nordisk's sales.
Elyse Ramsay's father, Tim, died suddenly after taking the weight-loss drug Saxenda for 19 days, leading his family to suspect the medication contributed to his death. Despite the coroner initially ruling the cause of death as 'undetermined', an investigation into Saxenda's role is ongoing. Elyse warns against using such drugs for non-diabetic weight loss due to potential severe side effects, highlighting the risks of obtaining them from unregulated sources.
Regulators are examining three reports of self-harm and suicidal thoughts among individuals taking Ozempic and Saxenda, both GLP-1 receptor agonists used for weight loss. The European Medicines Agency's Pharmacovigilance Risk Assessment Committee is leading the review, which will conclude by November 2023. It is unclear whether the reported incidents were due to an underlying mental health condition or a direct result of the medications. While suicide is not currently listed as a side effect of Ozempic, experts emphasize the importance of diligently reviewing any potential health concerns related to approved drugs. Novo Nordisk, the manufacturer of these drugs, stated that patient safety is a top priority and they continuously monitor data and real-world use. The FDA has not announced a review of GLP-1 receptor agonists but routinely evaluates approved drugs for safety.
The European Medicines Agency (EMA) is investigating Novo Nordisk's diabetes drug Ozempic and weight-loss treatment Saxenda after three cases of patients experiencing suicidal thoughts or self-harm were reported in Iceland. The EMA's safety committee is examining adverse events raised by the Icelandic Medicines Agency, including two cases of suicidal thoughts in individuals using Ozempic and Saxenda. Novo Nordisk stated that patient safety is their top priority and that their own safety monitoring has not found a causal association between the drugs and self-harming thoughts. The investigation also includes other medicines containing semaglutide or liraglutide, and the EMA may consider extending the review to other GLP-1 receptor agonists.
The European Medicines Agency (EMA) is investigating the popular diabetes and weight loss medications Ozempic and Saxenda, both made by Novo Nordisk, after a small number of users reported an increase in thoughts of suicide and self-harm. These drugs, known as GLP-1 agonists, are used to control blood sugar and aid in weight loss. The investigation will also consider whether other GLP-1 medications should be examined. While the risk is small, it has been known since clinical trials that GLP-1 drugs can increase the risk of suicidal ideation. Experts emphasize the importance of comprehensive management plans and emotional support when using these medications. Novo Nordisk maintains that there is no causal association between their products and suicidal thoughts.